Philip R. Reilly (Cornell AB ’69, Columbia JD ‘73, Yale MD ‘81) served as a Venture Partner at Third Rock Ventures in Boston, Massachusetts from 2008 through 2023. Trained in internal medicine and clinical genetics, he specializes in starting and launching companies to develop breakthrough therapies for heretofore untreatable genetic disorders. Among other roles, he has served on the boards of Edimer Pharmaceuticals and Lotus Tissue Repair, Inc. From 2010 to 2012 he was the interim Chief Medical Officer for bluebird bio, Inc, a gene therapy company. Prior to joining Third Rock Ventures, Dr. Reilly was (2000 – 2006) CEO and Chairman the Board of Interleukin Genetics, Inc. Prior to joining Interleukin, Dr. Reilly was the Executive Director of the Eunice Kennedy Shriver Center for Mental Retardation, Inc., a not-for-profit research organization dedicated to helping people with developmental disabilities, and an Assistant Professor at Harvard Medical School. Dr. Reilly served twice (2000 and 2003) as President of the American Society of Law, Medicine, and Ethics. From 1994-1997, he served on the Board of Directors of the American Society for Human Genetics. He is a founding fellow of the American College of Medical Genetics. Dr. Reilly was a trustee of Cornell University from 2006-2014. He is currently a member of the Board of Overseers of Weill Cornell Medical College. He also serves on the Advisory Council to the BU School of Public Health. He is the author of seven books about human genetics and more than 100 articles, many about public policy issues in genetics. His book, Orphan: The Quest to Save Children with Rare Genetic Disorders, was published in 2015.
Phil serves on the boards of several privately held biotech companies; chairs the SAB for Frontera, and serves as a consultant to Dompe Pharmaceuticals.
